Biotech stocks are breaking out. How Josh Brown is trading them

Merck and Moderna reported Phase 3 results for an individualized mRNA cancer vaccine (“intismeran autogene”) plus Keytruda in stage IIB–IV melanoma, hitting the primary endpoint of recurrence-free survival and improving distant metastasis-free survival—described as the first Phase 3 win for this mRNA + checkpoint inhibitor approach. The news drove a sharp repricing: Moderna surged more than 175% in a day before giving back ~20%, while Merck closed at $152.20 (all-time high) after gapping up from ~$137, with mRNA-linked names adding roughly $100B in market value. Separately, Amgen posted Q2 results of $10.1B revenue (+10%) and raised full-year guidance to $38.2–$39.4B revenue and non-GAAP EPS to $22.30–$23.50 (midpoint +$0.50), with the stock up ~35% YTD and making new all-time highs.

Analysis

MRK is the cleaner beneficiary because the market is now assigning more value to Keytruda durability and the probability that its franchise can be extended, not just defended. The revenue impact from the new combo is likely slow-burn, but the valuation effect can be immediate: a lower terminal-risk discount rate supports the multiple even before meaningful sales show up. The second-order loser set is the mature IO space—BMY, RHHBY, and other checkpoint-adjacent names need differentiated data, not just incremental updates, to avoid relative de-rating.

MRNA gets an option-value repricing, but that is a different quality of asset: one positive Phase 3 read-through does not solve manufacturing complexity, reimbursement friction, or throughput constraints for individualized therapy. That makes the move more fragile over the next 2-8 weeks than MRK’s rerating, because the cash-flow path is still uncertain even if the science is validated. If follow-on data or regulatory guidance suggests this is a narrow melanoma tool rather than a scalable oncology platform, the stock can give back a large fraction of the event move quickly.

AMGN is the steadier compounder here: breadth plus a guide raise should support multiple expansion relative to big pharma and to the broader biotech ETF. But at all-time highs, the trade is no longer about surprise upside; it is about whether growth can stay broad enough to justify a premium. Contrarian view: the market may be overestimating how quickly one high-profile oncology win can translate into sector-wide earnings power, so the better expression is quality long vs. beta, not chasing the most explosive headline name.

Key Decisions for Investors

• Long MRK on pullbacks toward the post-gap support zone; use a close back below the breakout area as the invalidation point. Target is 1-3 months of multiple expansion, not immediate revenue contribution.
• Pair trade: long MRK / short MRNA into strength for 2-6 weeks. Thesis is cash-flow durability vs. option-like platform hype; cover the short if MRNA holds the event premium and follows with additional validating data.
• Long AMGN vs short XBI as a quality-vs-beta relative value trade over 1-3 months. AMGN has the cleaner earnings revision story; the pair should work unless speculative biotech breadth broadens materially.
• Do not chase MRNA after the first spike without confirmation on manufacturing scale, reimbursement, or additional indications. Treat it as a watch item, not a core long, until the commercial path is clearer.
• Set alerts: MRK weekly close back inside the prior gap, or AMGN weekly close back below prior breakout support, would falsify the momentum thesis and argue for de-risking.